Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Mayo Clinic, Jacksonville, Florida.
Clin Gastroenterol Hepatol. 2024 Jun;22(6):1333-1335.e2. doi: 10.1016/j.cgh.2023.11.024. Epub 2023 Dec 2.
Glucagon-like peptide 1 (GLP-1) receptor agonists have transformed the treatment of type 2 diabetes and obesity. These agents have been associated with varying degrees of delay in gastric emptying, and a significant proportion of patients experience digestive side effects. There have been previous case reports of gastric retention of food and pulmonary aspiration during upper gastrointestinal (GI) endoscopy in the setting of GLP-1 receptor agonist use; however, the cumulative incidence has not been previously explored.
胰高血糖素样肽 1（GLP-1）受体激动剂改变了 2 型糖尿病和肥胖症的治疗方法。这些药物与胃排空延迟程度不同有关，相当一部分患者会出现消化道副作用。先前有病例报告称，在上消化道（GI）内窥镜检查中使用 GLP-1 受体激动剂时，会出现食物胃潴留和肺吸入；然而，之前并未探讨过其累积发生率。
